Finasteride is contraindicated in women, especially those who are pregnant or may become pregnant, because it can cause birth-defects. Female hair-loss treatments involve other agents, such as topical minoxidil.
Finasteride does not impair cognition or motor skills, so it does not affect the ability to drive or operate machinery. However, severe sexual side effects could indirectly impact concentration.
Visible hair regrowth typically begins after 3 to 6 months of daily use, with continued improvement up to 12 months. Early responders may notice reduced shedding within the first few weeks.
Take the missed tablet as soon as you remember on the same day. If it is already close to the time for the next dose, skip the missed one and continue with the regular schedule; do not double-dose.
There are no specific dietary restrictions. Finasteride can be taken with or without food, and normal meals do not interfere with its absorption.
Finasteride can lower PSA concentrations by up to 50 % after several months of therapy. Physicians should adjust PSA interpretation accordingly, especially when monitoring for prostate disease.
Symptoms may include rash, itching, swelling of the face or lips, and difficulty breathing. Seek immediate medical attention if any of these occur.
Routine blood testing is not required for the 1 mg hair-loss indication. However, baseline liver function may be considered in men with known hepatic disease.
Finasteride can be combined with topical minoxidil under medical supervision. The combination may enhance overall efficacy, but concurrent use should be discussed with a clinician.
Discontinuation generally leads to a gradual return of the pre-treatment hair-loss pattern within 6 to 12 months. Any gains achieved while on therapy may be lost over time.
Propecia is a prescription-only medication (POM) marketed in the United Kingdom for the treatment of male pattern hair loss, also known as androgenetic alopecia. Its active ingredient is finasteride, a synthetic 5-alpha-reductase inhibitor. Propecia is supplied as an oral pill in two strengths: 1 mg and 5 mg tablets. The 1 mg strength is the formulation licensed for hair-loss treatment; the 5 mg strength is also available for other indications, such as benign prostatic hyperplasia (BPH), under a different brand name.
Finasteride blocks the enzyme 5-alpha-reductase type II, which converts testosterone into dihydrotestosterone (DHT). DHT binds to androgen receptors in hair follicles and the prostate, promoting miniaturisation of hair shafts and enlargement of prostate tissue. By reducing DHT levels by about 70 % in the scalp, finasteride slows hair-follicle miniaturisation and can stimulate regrowth of thinning hair. The drug is absorbed after oral ingestion, reaches peak plasma concentrations within 2-6 hours, and is metabolised primarily in the liver. About 65 % of the dose is excreted in the urine, largely as inactive metabolites.
Androgenetic alopecia (male-pattern hair loss) - the only indication approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for the 1 mg formulation of Propecia. Treatment is intended for adult men with mild to moderate hair thinning on the crown and vertex.
Benign prostatic hyperplasia (BPH) - the 5 mg finasteride tablet is approved for BPH under a different brand (Proscar). Although the same active ingredient is used, the product name Propecia is not licensed for this indication.
Ideal candidates - adult males (≥18 years) with early-stage androgenetic alopecia who desire to preserve existing hair and promote regrowth.
Absolute contraindications
Known hypersensitivity to finasteride or any tablet excipient.
Women who are or may become pregnant, because finasteride can cause birth-defects in a male fetus.
Children and adolescents.
Relative contraindications
Severe liver impairment (finasteride is metabolised hepatically).
Existing hormonal disorders that could be aggravated by altered androgen levels.
Special populations
Pregnancy & lactation: Finasteride is contraindicated in women who are pregnant or may become pregnant. Men should store tablets out of reach of women and children.
Elderly: No dose adjustment is required solely based on age, but renal and hepatic function should be considered.
Patients with BPH: If a 5 mg dose is prescribed for prostate enlargement, dosing and monitoring follow separate clinical guidelines.
These effects are usually mild and reversible after discontinuation.
Patients should disclose all medications, supplements, and herbal products to their healthcare provider before starting Propecia.
This article provides educational information about Propecia and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
